Asset Details
Do you wish to reserve the book?
Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus
Do you wish to request the book?
Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus
2013
Overview
Objective The value of surveillance for patients with Barrett's oesophagus (BO) is under discussion given the overall low incidence of neoplastic progression and lack of discriminative tests for risk stratification. Histological diagnosis of low-grade dysplasia (LGD) is the only accepted predictor for progression to date, but has a low predictive value. The aim of this study was therefore to evaluate the value of p53 immunohistochemistry for predicting neoplastic progression in patients with BO. Design We conducted a case–control study within a prospective cohort of 720 patients with BO. Patients who developed high-grade dysplasia (HGD) or oesophageal adenocarcinoma (OAC) were classified as cases and patients without neoplastic progression were classified as controls. P53 protein expression was determined by immunohistochemistry in more than 12 000 biopsies from 635 patients and was scored independently by two expert pathologists who were blinded to long-term outcome. Results During follow-up, 49 (8%) patients developed HGD or OAC. P53 overexpression was associated with an increased risk of neoplastic progression in patients with BO after adjusting for age, gender, Barrett length and oesophagitis (adjusted relative risks (RRa) 5.6; 95% CI 3.1 to 10.3), but the risk was even higher with loss of p53 expression (RRa 14.0; 95% CI 5.3 to 37.2). The positive predictive value for neoplastic progression increased from 15% with histological diagnosis of LGD to 33% with LGD and concurrent aberrant p53 expression. Conclusions Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with BO and appears to be a more powerful predictor of neoplastic progression than histological diagnosis of LGD.
Publisher
BMJ Publishing Group Ltd and British Society of Gastroenterology,BMJ Publishing Group LTD
Subject
/ Aged
/ Barrett Esophagus - complications
/ Barrett Esophagus - metabolism
/ Barrett Esophagus - pathology
/ Biopsy
/ Esophageal Neoplasms - etiology
/ Esophageal Neoplasms - metabolism
/ Esophageal Neoplasms - pathology
/ Female
/ Humans
/ Male
/ Mutation
/ Precancerous Conditions - metabolism
/ Precancerous Conditions - pathology
/ Proteins
/ Studies
